Lead Time and Prognostic Role of Serum CEA, CA19-9, IL-6, CRP, and YKL-40 after Adjuvant Chemotherapy in Colorectal Cancer.
CA19-9
CEA
CRP
IL-6
YKL-40
colorectal cancer
lead time
post-adjuvant
prognostic biomarker
tumour marker
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
02 Aug 2021
02 Aug 2021
Historique:
received:
29
06
2021
revised:
23
07
2021
accepted:
26
07
2021
entrez:
7
8
2021
pubmed:
8
8
2021
medline:
8
8
2021
Statut:
epublish
Résumé
In colorectal cancer (CRC), 20-50% of patients relapse after curative-intent surgery with or without adjuvant therapy. We investigated the lead times and prognostic value of post-adjuvant (8 months from randomisation to adjuvant treatment) serum CEA, CA19-9, IL-6, CRP, and YKL-40. We included 147 radically resected stage II-IV CRC treated with 24 weeks of adjuvant 5-fluorouracil-based chemotherapy in the phase III LIPSYT-study (ISRCTN98405441). All 147 were included in lead time analysis, but 12 relapsing during adjuvant therapy were excluded from post-adjuvant analysis. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired disease-free survival (DFS) with hazard ratio (HR) 5.21 (95% confidence interval 2.32-11.69); 3.72 (1.99-6.95); 2.58 (1.18-5.61), respectively, and elevated IL-6 and CRP with impaired overall survival (OS) HR 3.06 (1.64-5.73); 3.41 (1.55-7.49), respectively. Elevated post-adjuvant IL-6 in CEA-normal patients identified a subgroup with impaired DFS. HR 3.12 (1.38-7.04) and OS, HR 3.20 (1.39-7.37). The lead times between the elevated biomarker and radiological relapse were 7.8 months for CEA and 10.0-53.1 months for CA19-9, IL-6, CRP, and YKL-40, and the lead time for the five combined was 27.3 months. Elevated post-adjuvant CEA, IL-6, and CRP were associated with impaired DFS. The lead time was shortest for CEA.
Identifiants
pubmed: 34359796
pii: cancers13153892
doi: 10.3390/cancers13153892
pmc: PMC8345682
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Int J Colorectal Dis. 2019 Apr;34(4):657-666
pubmed: 30671635
Cancers (Basel). 2019 Jun 21;11(6):
pubmed: 31234350
J Clin Oncol. 2015 Jun 1;33(16):1787-96
pubmed: 25918287
JAMA. 2014 Jan 15;311(3):263-70
pubmed: 24430319
Int J Surg. 2016 Jan;25:134-44
pubmed: 26700203
Oncotarget. 2018 Jul 3;9(51):29820-29841
pubmed: 30038723
World J Gastrointest Oncol. 2019 Dec 15;11(12):1206-1217
pubmed: 31908725
JAMA Oncol. 2019 Aug 1;5(8):1118-1123
pubmed: 31070668
Cancer Cell Int. 2019 Oct 10;19:259
pubmed: 31624472
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
World J Gastroenterol. 2016 Feb 7;22(5):1745-55
pubmed: 26855534
Anticancer Res. 2019 Nov;39(11):5867-5877
pubmed: 31704811
Am J Surg. 1998 Oct;176(4):335-8
pubmed: 9817250
Cancer Treat Rev. 2019 May;75:1-11
pubmed: 30849607
Acta Oncol. 2020 Dec;59(12):1416-1423
pubmed: 32790589
Cancers (Basel). 2019 Dec 04;11(12):
pubmed: 31817090
Cancer Invest. 2005;23(4):338-51
pubmed: 16100946
Nat Rev Clin Oncol. 2020 Dec;17(12):757-770
pubmed: 32632268
Cancer Med. 2013 Apr;2(2):234-42
pubmed: 23634291
Biosci Trends. 2015 Dec;9(6):393-401
pubmed: 26781797
J Exp Med. 1965 Mar 1;121:439-62
pubmed: 14270243
Br J Surg. 2016 Sep;103(10):1259-68
pubmed: 27488593
Pharmacol Ther. 2019 Nov;203:107394
pubmed: 31356910
Int J Colorectal Dis. 2010 May;25(5):567-71
pubmed: 20162425
Anticancer Res. 2015 Apr;35(4):2359-68
pubmed: 25862901
Int J Mol Sci. 2018 Jun 26;19(7):
pubmed: 29949857
Br J Cancer. 2019 Aug;121(4):312-317
pubmed: 31296923
Dis Colon Rectum. 1992 May;35(5):471-6
pubmed: 1568399
Int J Clin Oncol. 2017 Feb;22(1):96-101
pubmed: 27503134
Dis Colon Rectum. 1994 Sep;37(9):875-81
pubmed: 8076486
Ann Oncol. 2020 Oct;31(10):1291-1305
pubmed: 32702383
Ann Surg Oncol. 2000 Mar;7(2):133-8
pubmed: 10761792
Tumour Biol. 2014 Oct;35(10):10237-48
pubmed: 25027407
Acta Oncol. 2013 Nov;52(8):1691-8
pubmed: 24102179
Ann Surg Oncol. 2017 Jan;24(1):227-235
pubmed: 27699609
PLoS One. 2017 Mar 10;12(3):e0171810
pubmed: 28282381
Pancreatology. 2016 Jul-Aug;16(4):658-64
pubmed: 27178104
Int J Clin Exp Pathol. 2017 Oct 01;10(10):10441-10450
pubmed: 31966381
Cancer Res. 1997 Oct 1;57(19):4432-6
pubmed: 9331108
Cancers (Basel). 2020 Sep 29;12(10):
pubmed: 33003583
Ann Surg Oncol. 2009 Nov;16(11):3087-93
pubmed: 19629600
Oncotarget. 2016 Nov 15;7(46):75013-75022
pubmed: 27738330
Br J Cancer. 2007 Oct 22;97(8):1028-34
pubmed: 17895895
Cancer Med. 2016 Mar;5(3):426-33
pubmed: 26799163
Cancer Epidemiol Biomarkers Prev. 2006 Feb;15(2):194-202
pubmed: 16492905
PLoS One. 2020 Aug 5;15(8):e0236569
pubmed: 32756596
Arch Surg. 1995 Oct;130(10):1062-7
pubmed: 7575117
Cochrane Database Syst Rev. 2015 Dec 10;(12):CD011134
pubmed: 26661580
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Anticancer Res. 2009 Oct;29(10):4303-8
pubmed: 19846991
BMC Cancer. 2019 May 3;19(1):418
pubmed: 31053096
Br J Cancer. 1999 Mar;79(9-10):1494-9
pubmed: 10188896
Cochrane Database Syst Rev. 2019 Sep 04;9:CD002200
pubmed: 31483854
Gastroenterol Res Pract. 2016;2016:9701574
pubmed: 26858756